Navamedic ASA

Oslo Stock Exchange NAVA.OL

Navamedic ASA Interest Coverage Ratio for the year ending December 31, 2023: 1.76

Navamedic ASA Interest Coverage Ratio is 1.76 for the year ending December 31, 2023, a -97.72% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Navamedic ASA Interest Coverage Ratio for the year ending December 31, 2022 was 76.83, a 1,828.00% change year over year.
  • Navamedic ASA Interest Coverage Ratio for the year ending December 31, 2021 was 3.99, a 231.08% change year over year.
  • Navamedic ASA Interest Coverage Ratio for the year ending December 31, 2020 was -3.04, a 56.25% change year over year.
  • Navamedic ASA Interest Coverage Ratio for the year ending December 31, 2019 was -6.95, a -160.13% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
SV Wall Street
Oslo Stock Exchange: NAVA.OL

Navamedic ASA

CEO Ms. Kathrine E. Gamborg Andreassen
IPO Date March 31, 2006
Location Norway
Headquarters Henrik Ibsensgate 100
Employees 45
Sector Healthcare
Industries
Description

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

Similar companies

GOD.OL

Goodtech ASA

USD 0.83

-1.11%

MEDI.OL

Medistim ASA

USD 13.86

-1.83%

PHO.OL

Photocure ASA

USD 4.93

-3.23%

KIT.OL

Kitron ASA

USD 3.35

-2.28%

PCIB.OL

PCI Biotech Holding ASA

USD 0.11

3.20%

StockViz Staff

February 5, 2025

Any question? Send us an email